Frontiers in Pharmacology

ISSN: 1663-9812
Publisher: Frontiers Research Foundation / Frontiers Media

Publications (23)

close-button

Types of publications

Journal article
Unpublished / Preprint

Publication year

From
To

Abstract

Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction (2023) Zheng Y, Yang W, Jia Y, Ji J, Wu L, Feng J, Li Y, et al. Journal article A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing (2022) Chen XZ, Guo R, Zhao C, Xu J, Song H, Yu H, Pilarsky C, et al. Journal article, Review article Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment (2021) Thoma OM, Neurath M, Waldner M Journal article, Review article Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble delta 9-THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism (2021) Iman IN, Ahmad NAZ, Yusof NAM, Talib UN, Norazit A, Kumar J, Mehat MZ, et al. Journal article Repeated Use of Prescription Drugs in Pediatrics: Comprehensive Overview Based on German Claims Data (2021) Scholle O, Neubert A, Riedel O, Toni I, Haug U Journal article Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats (2021) Hassan R, Sreenivasan S, Muller CP, Hassan Z Journal article Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease (2021) Lueke F, Harrer DC, Menhart K, Wolff D, Holler E, Hellwig D, Herr W, et al. Journal article Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy (2021) Lueke F, Harrer DC, Hahn J, Grube M, Pukrop T, Herr W, Reichle A, Heudobler D Journal article Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models (2021) Haberkorn B, Fromm M, König J Journal article, Review article A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung) (2021) Heudobler D, Schulz C, Fischer JR, Staib P, Wehler T, Suedhoff T, Schichtl T, et al. Journal article
1 2 3